SCHEMBL22124500

SCHEMBL22124500

COc1ccc(-c2cnc3c(Nc4cc(F)c(C(=O)NCCOCCN)c(Br)c4)nccn23)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ZAP70 P43403 11/20 0.35
▸ KARS1 Q15046 10/20 0.35
▸ SYK P43405 4/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ TTK P33981 2/20 0.33
▸ PTK2 Q05397 3/20 0.32
▸ ADRA2B P18089 1/20 0.31
▸ MAPKAPK5 Q8IW41 1/20 0.31
▸ FLT1 P17948 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349879 1.00 ZAP70 (0.35) ZAP70KARS1SYKPDE10ATTK
Hydrochloric Acid SCHEMBL30349952 0.99 ZAP70 (0.34) ZAP70KARS1SYKPDE10ATTK
SCHEMBL22125062 0.95 ZAP70 (0.37) ZAP70KARS1SYKPDE10ATTK
SCHEMBL22124722 0.92 PDE10A (0.35) ZAP70KARS1SYKPDE10ATTK
SCHEMBL30171946 0.92 ZAP70 (0.35) ZAP70KARS1SYKPDE10ATTK
SCHEMBL24916638 0.92 PDE10A (0.35) ZAP70KARS1SYKPDE10ATTK
SCHEMBL22124926 0.92 ZAP70 (0.35) ZAP70KARS1SYKPDE10ATTK
SCHEMBL22124854 0.92 PDE10A (0.35) ZAP70KARS1SYKPDE10ATTK
Hydrochloric Acid SCHEMBL30349748 0.92 PDE10A (0.35) ZAP70KARS1SYKPDE10ATTK
SCHEMBL22124567 0.90 SYK (0.36) SYKTTKMAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898630-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-05-10 — — EP claimed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US claimed
EP-3898630-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2021-10-27 — — EP claimed
WO-2020126954-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2020-06-25 — — WO claimed
EP-3898630-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-05-10 — — EP disclosed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed
EP-3898630-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2021-10-27 — — EP disclosed
WO-2020126954-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 ZAP70 716/4885KARS1 610/4885SYK 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback